Abciximab ( HY355016 ) is a research-grade recombinant antibody targeting CD41 . Produced in mammalian cells with native-like glycosylation. Highlights Research Grade — For PK/PD studies, assay development, and ADA research. Native Glycosylation — Mammalian expression ensures native-like patterns.